<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04400084</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190817</org_study_id>
    <nct_id>NCT04400084</nct_id>
  </id_info>
  <brief_title>Using Cotyledon Perfusion to Study Drugs Transfer Across the Placenta</brief_title>
  <acronym>DRUGS-PTP</acronym>
  <official_title>Ex Vivo Study of Drugs Transfer Across the Placenta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug prescriptions are usual during pregnancy however women and their fetuses still remain an&#xD;
      orphan population with regard to drugs efficacy and safety clinical studies. Most xenobiotics&#xD;
      diffuse through the placenta and some of them can alter fetus development resulting in&#xD;
      structural abnormalities, growth or functional deficiencies. The aim of the study is to study&#xD;
      the drug transfer using human placenta after delivery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For ethical reasons, pregnant woman are not included in clinical trials so that data&#xD;
      regarding safety and efficacy of many drugs are scarce. It is known that xenobiotics across&#xD;
      the placental barrier but studies regarding quantity and mechanisms of this transfer remain&#xD;
      insuffisant. Among the different methodologies to evaluate drug transfer, perfusion of human&#xD;
      cotyledon is one of the most relevant ones. The two sides of the cotyledon, fetal and&#xD;
      maternal ones, are perfused within the hour after delivery with EARLE medium in a double&#xD;
      closed circuit. The studied drug (it can be any drug given to pregnant mothers) and&#xD;
      antipyrine (the control molecule) are added at the beginning of the three hours perfusion&#xD;
      realized at 37°C, with maternal flow rate of 12ml/min and fetal one of 6ml/min. Samples are&#xD;
      collected along the perfusion and the drugs dosage will be done in the pharmacology&#xD;
      department of Cochin Hospital. Tissues of the cotyledon will be also collected to study the&#xD;
      proteins, and ARNs expressed. The drug concentrations will be analyzed by calculating fetal&#xD;
      to maternal concentrations ratios and a fetal transfer rate (fetal drug quantity on total&#xD;
      drug quantity at the end of the perfusion). Then modelling on Monolix software will be done&#xD;
      to estimate the transfer constants across the two compartments. Modelling will allow to&#xD;
      estimate the interindividual variability and to test covariables like sex, gestation&#xD;
      duration, genetics, or protein expression. Proteins will be studied by an appropriated method&#xD;
      (western blot, or proteomic analysis). The genetics study will consist in candidate gene&#xD;
      approach. Polymorphisms will be chosen in genes coding for transporters or enzymes or their&#xD;
      regulators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2020</start_date>
  <completion_date type="Anticipated">June 2030</completion_date>
  <primary_completion_date type="Anticipated">June 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fetal transfer rate</measure>
    <time_frame>At 180 minutes (end of the perfusion)</time_frame>
    <description>Quantity of drug transferred into fetal compartment/ quantity of drug in the two compartments *100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of concentrations</measure>
    <time_frame>At 180 minutes (end of the perfusion)</time_frame>
    <description>Fetal concentration / maternal concentration *100</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Normal Pregnancy</condition>
  <arm_group>
    <arm_group_label>Pregnant mothers</arm_group_label>
    <description>Pregnant mothers who have a normal pregnancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placenta perfusion</intervention_name>
    <description>Placenta perfusion in double closed circuit, during 3 hours</description>
    <arm_group_label>Pregnant mothers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women who give birth in the Port-Royal maternity (Paris)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pregnant women older than 18 years,&#xD;
&#xD;
          -  patient with social security or health insurance,&#xD;
&#xD;
          -  from the 24th week of amenorrhea,&#xD;
&#xD;
          -  patient who has given her consent,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Maternal pathologies pre-existing pregnancy :&#xD;
&#xD;
               -  diabetes-like vascular disease,&#xD;
&#xD;
               -  arterial hypertension,&#xD;
&#xD;
               -  known prothrombotic pathology, history of venous thrombosis or pulmonary&#xD;
                  embolism,&#xD;
&#xD;
               -  maternal serology HIV+, BHV+, CHV+ and syphilis,&#xD;
&#xD;
          -  Pregnancy and fetal pathologies :&#xD;
&#xD;
               -  pre-eclampsia,&#xD;
&#xD;
               -  delayed growth in utero (can affect placental circulation),&#xD;
&#xD;
               -  gestational diabetes without insulin,&#xD;
&#xD;
               -  fetal malformation,&#xD;
&#xD;
               -  known genetic pathology,&#xD;
&#xD;
          -  Patient under tutorship or curatorship, or not speaking french,&#xD;
&#xD;
          -  Patient who has not given her consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Marc TRELUYER, Pr</last_name>
    <phone>00 33 1 58 41 28 85</phone>
    <email>jean-marc.treluyer@parisdescartes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie BENHAMMANI-GODARD</last_name>
    <phone>00 33 1 54 41 12 11</phone>
    <email>marie.godard@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIC Port-Royal-Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille LE RAY</last_name>
      <phone>00 33 1 58 41 38 17</phone>
      <email>camille.le-ray@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Schneider H, Panigel M, Dancis J. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am J Obstet Gynecol. 1972 Nov 15;114(6):822-8.</citation>
    <PMID>4676572</PMID>
  </reference>
  <reference>
    <citation>Hutson JR, Garcia-Bournissen F, Davis A, Koren G. The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs. Clin Pharmacol Ther. 2011 Jul;90(1):67-76. doi: 10.1038/clpt.2011.66. Epub 2011 May 11. Review. Erratum in: Clin Pharmacol Ther. 2011 Sep;90(3):479.</citation>
    <PMID>21562489</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Placenta</keyword>
  <keyword>Drug</keyword>
  <keyword>Transplacental transfer</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

